Handelsbanken Fonder’s Seres Therapeutics MCRB Stock Holding History

Handelsbanken Fonder’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-55,000	Closed	-$852K	–	1562
2024 Q1	$852K	Hold	55,000	–	–	﹤0.01%	905
2023 Q4	$1.54M	Buy	55,000 +5,000	+10%	+$131K	0.01%	631
2023 Q3	$2.38M	Hold	50,000	–	–	0.01%	516
2023 Q2	$4.79M	Buy	50,000 +10,000	+25%	+$1.09M	0.03%	434
2023 Q1	$4.54M	Buy	+40,000	New	+$4.33M	0.03%	428
2021 Q4	–	Sell	-1,825	Closed	-$254K	–	1753
2021 Q3	$254K	Buy	1,825 +1,025	+128%	+$201K	﹤0.01%	1622
2021 Q2	$382K	Buy	800 +100	+14%	+$42.2K	﹤0.01%	1550
2021 Q1	$288K	Buy	+700	New	+$322K	﹤0.01%	1462

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Handelsbanken Fonder's MCRB Position: Q2 2024 in Review

Handelsbanken Fonder sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 55,000 shares — an estimated $852K sold.

Handelsbanken Fonder first reported a position in MCRB in Q1 2021 and held it in 8 quarters. The position peaked at $4.79M in Q2 2023. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

Handelsbanken Fonder reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
Handelsbanken Fonder sold 55,000 Seres Therapeutics shares in Q2 2024, an estimated $852K.
Handelsbanken Fonder first reported a position in Seres Therapeutics in Q1 2021 and held it in 8 quarters.
Handelsbanken Fonder's Seres Therapeutics position peaked at $4.79M in Q2 2023.
93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on Handelsbanken Fonder's 13F filing for Q2 2024, filed 5 Aug 2024.